baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Regeneron Pharmaceuticals/ US75886F1075 /

5/17/2024 5:13:13 PM	Chg. +6.72	Volume	Bid5:33:40 PM	Ask5:34:55 PM	Market Capitalization	Dividend Y.	P/E Ratio
976.04USD	+0.69%	3,958 Turnover: 1.85 mill.	972.59Bid Size: 1	977.72Ask Size: 1	107.54 bill.USD	-	26.34

GlobeNewswire 5/14 Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Sci...

GlobeNewswire 5/14 Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer

GlobeNewswire 5/13 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...

GlobeNewswire 5/10 Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire 5/9 Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company P...

GlobeNewswire 5/8 Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound G...

GlobeNewswire 5/7 Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference

GlobeNewswire 5/6 Regeneron Announces Investor Conference Presentations

GlobeNewswire 5/2 Regeneron Reports First Quarter 2024 Financial and Operating Results

GlobeNewswire 4/29 EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Mean...

GlobeNewswire 4/26 Medigene AG reports Financial Results and Business Update for Q1 2024

GlobeNewswire 4/25 Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing fo...

GlobeNewswire 4/24 Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad R...

GlobeNewswire 4/23 Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution

GlobeNewswire 4/22 Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Th...

GlobeNewswire 4/18 Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals,...

GlobeNewswire 4/18 REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Beh...

GlobeNewswire 4/16 Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024

GlobeNewswire 4/16 Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders

GlobeNewswire 4/15 Regeneron Ventures Launches with $500 Million Commitment to Fuel Promising Biotechnology Innovation

GlobeNewswire 4/11 INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Phar...

GlobeNewswire 4/9 Opthea Appoints John Han, PharmD, as VP Medical Affairs

GlobeNewswire 4/7 Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in ...

GlobeNewswire 4/1 Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and ...

GlobeNewswire 3/25 Regeneron Provides Update on Biologics License Application for Odronextamab

Regeneron Pharmaceuticals/ US75886F1075 /

If you wish to receive reply to your feedback, please provide your email address.